Summary

Bryan Johnson, a 46-year-old tech multimillionaire focused on anti-aging, stopped using rapamycin—a supplement he took for five years—after research suggested it might accelerate aging.

Johnson cited side effects like skin infections and glucose issues, as well as findings from a recent study showing rapamycin could worsen epigenetic aging.

Known for extreme anti-aging experiments, Johnson also created the health startup Blueprint, which markets pricey supplements.

His controversial methods, including teenage blood transfusions and genital shock treatments, have raised skepticism about their effectiveness and safety.

  • FundMECFSResearch
    link
    fedilink
    arrow-up
    16
    ·
    20 hours ago

    When you’ve got everything in life and all you want to do is live longer.

    instead of helping the billions living in squalor and dying premature deaths.

    • FaceDeer@fedia.io
      link
      fedilink
      arrow-up
      5
      ·
      15 hours ago

      If he hits on an effective anti-aging treatment from his efforts then he’ll help billions that way instead. Pretty much everyone eventually suffers from aging if they live long enough.

      • FundMECFSResearch
        link
        fedilink
        arrow-up
        7
        ·
        15 hours ago

        I applaud your otimism in thinking it will be democratised and not a luxury for wealthy classes.

        • FaceDeer@fedia.io
          link
          fedilink
          arrow-up
          6
          ·
          14 hours ago

          Almost all medications start out as a luxury for wealthy classes.

          When insulin was first discovered as a treatment for diabetes the first Americans to be treated with it back in 1922 were James D. Havens, son of former congressman James S. Havens, and Elizabeth Hughes Gossett, daughter of the US Secretary of State. I can just imagine the Reddit threads at the time decrying how diabetes research was only benefiting the “elites.” But nowadays insulin is manufactured in bulk and anyone can have access to it.